Vilazodone in the treatment of major depressive disorder: Efficacy across symptoms and severity of depression

International Clinical Psychopharmacology

Volumn 29, Issue 2, 2014, Pages 86-92

  Khan, Arif ^a,b   Sambunaris, Angelo ^c   Edwards, John ^d   Ruth, Adam ^e   Robinson, Donald S ^f  

^a Northwest Clinical Research Center   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Behavioral Medicine Institute of Atlanta   (United States)

^d FOREST RESEARCH INSTITUTE   (United States)

^e Prescott Medical Communications Group   (United States)

^f Worldwide Drug Development   (United States)

Author keywords

Antidepressant; Major Depressive Disorder; Selective Serotonin Reuptake Inhibitors; Serotonin 1A Receptor Agonists; Vilazodone

Indexed keywords

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BENZOFURANS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84895072074     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000016     Document Type: Article

References (35)

1. American Psychiatric Associ ation (2000). Diagnostic and Statistical Manual of Mental Disorders. Fourth edition, text revision Washington, DC: American Psychiatric Association.
2. Bakish D (1991). Fluoxetine potentiation by buspirone: Three case histories. Can J Psychiatry 36:749-750.
3. Blier P,Ward NM (2003). Is there a role for 5-HT1A agonists in the treatment of depression Biol Psychiatry 53:193-203.
4. Cipriani A, Barbui C, Bra mbilla P, Furukawa TA, Hotopf M, Geddes JR (2006). Are all antidepressants really the same The case of fluoxetine: A systematic review. J Clin Psychiatry 67:850-864.
5. Citrome L (2012). Vilazodone f or major depressive disorder: A systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed Int J Clin Pract 66:356-368.
6. Daly EJ, Trivedi MH,Wisniewski SR, Nierenberg AA, Gaynes BN,Warden D, et al. (2010). Health-related quality of life in depression: A STAR*D report. Ann Clin Psychiatry 22:43-55.
7. Demyttenaere K, Enzlin P, Dewe W, Boulanger B, De Bie J, De Troyer W, Mesters P (2001). Compliance with antidepressants in a primary care setting, 2: The influence of gender and type of impairment. J Cli n Psychiatry 62 (Suppl 22): 34-37.
8. Egede LE (2007). Major depression in individuals with chronic medical disorders: Prevalence, correlates and association with health resource utilization, lost productivity and functional di sability. Gen Hosp Psychiatry 29:409-416.
9. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK (2003). The economic burden of depression in the United States : How did it change between 1990 and 2000 J Clin Psychiatry 64:1465-1475.
10. Guy W (1976). The Clinician Global Severity and Impression Scales. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare publication (ADM), National Institute of Mental Health. Rockville, MD: National Institute of Mental Health. 218-222.
11. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
12. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
13. Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, Hagan JJ, et al. (2005). Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Ph armacol 510:49-57.
14. Katon W, Lin EH, Kroenke K (2007). The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry 29:147-155.
15. Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, et al. (2011). A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of maj or depressive disorder. J Clin Psychiatry 72:441-447.
16. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008). Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5:e45.
17. Liebowitz M, Croft HA, Kajdasz DK, Whalen H, Gallipoli S, Athanasiou M, Reed CR (2011). The safety and tolerability profil e of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Psychopharmacol Bull 44:15-33.
18. Menza M, Marin H, Opper RS (2003). Residual symptoms in depression: Can treatment be symptom-specific J Clin Psychiatry 64:516-523.
19. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
20. Montgomery SA, Moller HJ (2009). Is the significant superiority of escitalopram compared with other antidepressants clinically relevant Int Clin Psychopharmacol 24:111-118.
21. Nemeroff CB (2007). The burden of severe depression: A review of diagnostic challenges and treatment alternatives. J Psychiatr Res 41:189-206.
22. Nierenberg AA, Husain MM, Trivedi MH, Fava M,Warden D,Wisniewski SR, et al. (2010). Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: A STAR*D report. Psychol Med 40:41-50.
23. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC (2007). Are antid epressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder A meta-analysis of studies of newer agents. Biol Psychiatry 6 2:1217-1227.
24. Rickels K, Athanasiou M, Robinson DS, Gibertini M,Whalen H, Reed CR (2009). Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: A randomized, double -blind, placebo-controlled trial. J Clin Psychiatry 70:326-333.
25. Robinson DS, Kajdasz DK, Gallipoli S, Whalen H, Wamil A, Reed CR (2011). A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmaco l 31: 643-646.
26. Schatzberg AF (1999). Antidepressant effectiveness in severe depression and melancholia. J Clin Psychiatry 60 (Suppl 4):14-21, Discussion 22.
27. Sheehan DV, Lecrubier Y, S heehan KH, Amorim P, Janavs J, Weiller E, et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J C lin Psychiatry 59 (Suppl 20):22-33, Quiz 34-57.
28. Stewart JA, Deliyannides DA, Hellerstein DJ, McGrath PJ, Stewart JW (2012). Can people with nonsevere major depression benefit from antidepressant medication J Clin Psychiatry 73:518-525.
29. Sussman N (2003). Depression and painful physical symptoms. Prim Care Companion J Clin Psychiatry 5:19-26.
30. Szegedi A, Jansen WT, van Willigenburg AP, van Der Meulen E, Stassen HH, Thase ME (2009). Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: A metaanalysis including 6562 patients. J Clin Psychiatry 70:344-353.
31. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z (2006). Early onset of selective serotonin reuptake inhibitor antidepressa nt action: Systematic review and meta-analysis. Arch Gen Psychiatry 63:1217-1223.
32. Thase ME (2000). Treatment of severe depression. J Clin Psychiatry 61 (Suppl 1):17-25.
33. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 163:28-40.
34. Zajecka JM (2003). Treating depression to remission. J Clin Psychiatry 64 (Suppl 15):7-12.
35. Zimmerman M, Posternak MA, Chelminski I (2004). Derivation of a definiti on of remission on the Montgomery-Asberg Depression Rating Scale corresponding to the definition of remission on the Hamilton rating scale for depression. J Psychiatr Res 38:577-582.